vTv Therapeutics Inc. (NASDAQ:VTVT) Files An 8-K Unregistered Sales of Equity Securities

vTv Therapeutics Inc. (NASDAQ:VTVT) Files An 8-K Unregistered Sales of Equity Securities
Item 3.02 Unregistered Sale of Securities

Story continues below

On March 24, 2017, vTv Therapeutics Inc. (the “Company”) borrowed $7.5 million representing the second tranche under its Venture Loan and Security Agreement (the “Loan Agreement”), dated October 28, 2016, with Horizon Technology Finance Corporation (“Horizon”) and Silicon Valley Bank (“SVB”, and together with Horizon, the “Lenders”).  The commitment for the second tranche under the Loan Agreement was scheduled to expire on March 31, 2017.  In connection with this borrowing, the Company issued to the Lenders warrants to purchase 38,006 shares of the Company’s Class A common stock (“Warrants”), at a per share exercise price of $5.92, resulting in an aggregate exercise price representing 3.0% of the amount available under the second tranche.  The Warrants will expire on October 28, 2023.

The Company issued the Warrants in reliance on the exemption from registration provided for under Section 4(a)(2) of the Securities Act of 1933, on the basis that the issuance did not involve a public offering.


About vTv Therapeutics Inc. (NASDAQ:VTVT)

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial. Its type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. It has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.

vTv Therapeutics Inc. (NASDAQ:VTVT) Recent Trading Information

vTv Therapeutics Inc. (NASDAQ:VTVT) closed its last trading session up +0.47 at 6.38 with 11,105 shares trading hands.

An ad to help with our costs